TRodelvy use in AdvanCed TrIple Negative BrEast Cancer in Australia (TRACIE)
Not Applicable
Recruiting
- Conditions
- Breast Cancer onlyCancer - Breast
- Registration Number
- ACTRN12623000931673
- Lead Sponsor
- Walter and Eliza Hall Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
1.Patients with metastatic, or inoperable, locally advanced TNBC (either relapsed or de novo metastatic)
2.Patients who started SG during the patient identification period according to the locally approved indication:
Treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received at least two prior systemic therapies, including at least one prior therapy for locally advanced or metastatic disease”
Exclusion Criteria
1.Patients participating in any interventional clinical trials during SG treatment
2.History of SG use prior to first administration for advanced TNBC
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method